Statement of Ownership (sc 13g)
February 01 2017 - 5:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. ________)*
PROTALIX
BIOTHERAPEUTICS, INC.
(Name
of Issuer)
Common
Stock, par value $0.001 per share
|
(Title
of Class of Securities)
(CUSIP
Number)
2
Snunit Street, Science Park, POB 455, Carmiel 20100, Israel
972-4-988-9488
(Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January
26, 2017
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
o
Rule 13d-1(b)
x
Rule 13d-1(c)
o
Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No.
74365A101
|
|
13G
|
|
Page
2 of 5 Pages
|
|
|
|
|
|
1.
|
|
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abir Therapeutics Ltd
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
o
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Israel
|
|
|
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
5.
|
|
SOLE
VOTING POWER
6,200,000
|
|
6.
|
|
SHARED
VOTING POWER
0
|
|
7.
|
|
SOLE
DISPOSITIVE POWER
6,200,000
|
|
8.
|
|
SHARED
DISPOSITIVE POWER
0
|
|
|
|
|
|
9.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,200,000
|
|
|
10.
|
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)
o
|
|
|
11.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.0%
|
|
|
12.
|
|
TYPE
OF REPORTING PERSON (see instructions)
CO
|
|
|
|
|
|
|
|
|
|
|
|
|
CUSIP No.
74365A101
|
|
13G
|
|
Page
3 of 5 Pages
|
|
|
|
|
|
Item
1.
|
(a)
|
Name
of Issuer
Protalix BioTherapeutics, Inc.
|
|
|
|
|
(b)
|
Address
of Issuer’s Principal Executive Offices
2 Snunit Street, Science Park, POB 455, Carmiel 20100, Israel
|
|
|
|
Item
2.
|
(a)
|
Name
of Person Filing
Abir Therapeutics Ltd
|
|
|
|
|
(b)
|
Address of the
Principal Office or, if none, residence
3400 Boulevard De Maisonneuve West, Suite 1055, Montreal, Quebec Canada H3Z 3B8
|
|
|
|
|
(c)
|
Citizenship
Israel
|
|
|
|
|
(d)
|
Title of Class
of Securities
Common Stock, par value $0.001 per share
|
|
|
|
|
(e)
|
CUSIP Number
74365A101
|
|
|
|
Item
3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person
filing is a:
|
(a)
|
o
|
Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
(b)
|
o
|
Bank as defined
in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
(c)
|
o
|
Insurance company
as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
(d)
|
o
|
Investment company
registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
|
|
|
|
(e)
|
o
|
An investment
adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
o
|
An employee benefit
plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
o
|
A parent holding
company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
(h)
|
o
|
A savings associations
as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
|
|
|
(i)
|
o
|
A church plan
that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);
|
|
|
|
|
|
(j)
|
o
|
Group, in accordance
with §240.13d-1(b)(1)(ii)(J).
|
|
|
|
|
|
|
|
|
|
CUSIP No.
74365A101
|
|
13G
|
|
Page
4 of 5 Pages
|
|
|
|
|
|
Item
4. Ownership.
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
|
|
|
|
|
(a)
|
Amount
beneficially owned: 6,200,000
|
|
|
|
|
|
(b)
|
Percent
of class: 5.0%
|
|
|
|
|
|
(c)
|
Number
of shares as to which the person has: 6,200,000
|
|
|
|
|
|
|
(i)
|
Sole power to
vote or to direct the vote 6,200,000
|
|
|
|
|
|
|
(ii)
|
Shared power to
vote or to direct the vote 0
|
|
|
|
|
|
|
(iii)
|
Sole power to
dispose or to direct the disposition of 6,200,000
|
|
|
|
|
|
|
(iv)
|
Shared power to
dispose or to direct the disposition of 0
|
Instruction
.
For computations regarding securities which represent a right to acquire an underlying security
see
§240.13d-3(d)(1).
Item
5. Ownership of Five Percent or Less of a Class.
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following
o
.
Instruction
.
Dissolution of a group requires a response to this item.
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
Not
applicable
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company.
Not
applicable
Item
8. Identification and Classification of Members of the Group.
Not
applicable
Item
9. Notice of Dissolution of Group.
Not
applicable
|
|
|
|
|
CUSIP No.
74365A101
|
|
13G
|
|
Page
5 of 5 Pages
|
|
|
|
|
|
Item
10. Certification.
|
|
|
|
(a)
|
The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
|
|
|
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
|
|
|
|
(b)
|
The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
|
|
|
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
01/27/2017
|
|
Date
|
|
|
|
/s/ Jeffrey Kadanoff
|
|
Signature
|
|
|
|
Corporate Secretary
|
|
Name/Title
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024